News | May 04, 2024
Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
2024 full-year revenue guidance raised by US$ 2 billion
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
